Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology.
Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine.
The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target.
Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington.
As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 13, 24 | 0.00 Increased by +100.00% | -0.54 Increased by +100.00% |
| Mar 28, 24 | 0.00 Increased by +100.00% | -0.51 Increased by +100.00% |
| Nov 14, 23 | -0.44 Increased by +20.00% | -0.57 Increased by +22.81% |
| Aug 14, 23 | -0.59 Decreased by -3.51% | -0.60 Increased by +1.67% |
| May 10, 23 | -0.60 Increased by 0.00% | -0.59 Decreased by -1.69% |
| Mar 30, 23 | -0.59 Decreased by -28.26% | -0.59 |
| Nov 14, 22 | -0.55 Increased by +57.69% | -0.57 Increased by +3.51% |
| Aug 15, 22 | -0.57 Increased by +80.07% | -0.55 Decreased by -3.64% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by N/A% | -22.04 M Decreased by -5.92% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -26.50 M Decreased by -19.67% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -22.60 M Increased by +3.47% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Increased by +100.00% | -21.48 M Decreased by -18.14% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by -100.00% | -20.81 M Increased by +39.48% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by -100.00% | -22.14 M Decreased by -158.90% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by -100.00% | -23.41 M Decreased by -300.15% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | -5.73 M Decreased by -454.70% | -18.18 M Decreased by -294.57% | Increased by +317.20% Increased by +211.24% |